<DOC>
	<DOCNO>NCT01869205</DOCNO>
	<brief_summary>To assess efficacy bronchoscopic lung volume reduction Korean emphysema patient</brief_summary>
	<brief_title>The Effect Mechanism Bronchoscopic Lung Volume Reduction Endobronchial Valve Korean Emphysema Patients</brief_title>
	<detailed_description>The prevalence chronic obstructive pulmonary disease ( COPD ) high ( 13.4 % ) . In addition , COPD rank 10th among cause death Korea , rise 7th 2008 . Airflow limitation COPD cause mixture small airway disease ( obstructive bronchiolitis ) parenchyma destruction ( emphysema ) . Bronchodilator anti-inflammatory drug , corticosteroid effective obstructive bronchiolitis . However , drug effective emphysema . Lung volume reduction devise remove hyperinflated lung , function remain lung . Surgical lung volume reduction show improve survival select emphysema patient . However , surgical lung volume reduction bee perform rarely due significant surgery-related mortality . In regard , non-surgical lung volume reduction method develop . Of , bronchoscopic lung volume reduction endobronchial one-way valve mostly use method show low early complication surgery . The bronchoscopic lung volume reduction use endobronchial valve prove efficacy safety several large clinical trial . Although procedure-related complication acute exacerbation COPD , pneumonia , hemoptysis , patient receive endobronchial valve show improved lung function , exercise capacity quality life . The endobronchial valve get approved Conformity European ( CE ) Mark Europe . In follow-up study patient endobronchial valve , efficacy survival patient dependent atelectasis induce valve . Collateral ventilation play key role endobronchial valve-induced atelectasis . Therefore , assessment collateral ventilation precede insert endobronchial valve . Computed tomography ( CT ) visualize characterize morphologic change lung patient COPD . Lung perfusion ventilation CT protocols develop quantitative assessment COPD medical treatment . The CT protocol expect select optimal patient endobronchial valve evaluate efficacy . We attempt evaluate efficacy bronchoscopic lung volume reduction use lung perfusion ventilation CT outcome .</detailed_description>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>Age 40 75 Patients smoke history heterogenous emphysema chest CT Advanced emphysema ( FEV1/FVC &lt; 70 % , FEV1 1545 % , TLC &gt; 100 % RV &gt; 150 % predict ) Persistent symptoms refractory treatment PaCO2 &lt; 50 mmHg PaO2 &gt; 45 mmHg Body mass index ( BMI ) ≤31.1 kg/m2 ( men ) ≤32.3 kg/m2 ( woman ) 6min walk distance &gt; 140 pulmonary rehabilitation Diffusing capacity ( DLco ) &lt; 20 % predict Large bulla ( exceed 5 cm ) Alpha1 antitrypsin deficiency History thoracotomy Excessive sputum production ( throughout week ) Severe pulmonary hypertension ( systolic pulmonary artery pressure ≥ 45mmHg , estimate peak velocity tricuspid regurgitant jet doppler echocardiography ) Acute respiratory infection Unstable angina , congestive heart failure , acute myocardial infarction 6 month</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>COPD</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Bronchoscopic lung volume reduction</keyword>
	<keyword>Endobronchial valve</keyword>
</DOC>